We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
-7.64%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$563M
AUM Growth
-$101M
(-15%)
Cap. Flow
-$27M
Cap. Flow
% of AUM
-4.8%
Top 10 Holdings %
Top 10 Hldgs %
25.13%
Holding
123
New
15
Increased
30
Reduced
43
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$13.2M |
| 2 |
HealthEquity
HQY
|
+$13M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$7.95M |
| 4 |
Tandem Diabetes Care
TNDM
|
+$7.45M |
| 5 |
ITOS
iTeos Therapeutics
ITOS
|
+$5.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$21.4M |
| 2 |
Alignment Healthcare
ALHC
|
+$10.3M |
| 3 |
Definitive Healthcare
DH
|
+$7.8M |
| 4 |
TG Therapeutics
TGTX
|
+$7.6M |
| 5 |
NVTA
Invitae Corporation
NVTA
|
+$6.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.69% |
| 2 | Industrials | 4.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Eli Lilly
LLY
$1.02T
| $8.15M | 1.45% |
28,465
-1,000
| -3% | -$257K |
|
|
27
BioMarin Pharmaceuticals
BMRN
$11.6B
| $8.11M | 1.44% |
105,130
+95,000
| +938% | +$7.95M |
|
|
TPTX
28
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $7.54M | 1.34% |
280,850
+61,100
| +28% | +$2.05M |
|
|
ITOS
29
DELISTED
iTeos Therapeutics
ITOS
| $7.54M | 1.34% |
234,150
+154,150
| +193% | +$5.6M |
|
30
Fate Therapeutics
FATE
$286M
| $7.49M | 1.33% |
193,160
| – | – |
|
|
SWAV
31
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $7.26M | 1.29% |
35,000
| – | – |
|
32
Abbott
ABT
$183B
| $7.04M | 1.25% |
59,498
-9,050
| -13% | -$1.12M |
|
33
Denali Therapeutics
DNLI
$3.65B
| $6.66M | 1.18% |
207,100
+17,500
| +9% | +$602K |
|
34
Health Catalyst
HCAT
$154M
| $6.58M | 1.17% |
251,739
+10,000
| +4% | +$284K |
|
|
SGEN
35
DELISTED
Seagen Inc. Common Stock
SGEN
| $5.92M | 1.05% |
41,130
+4,200
| +11% | +$568K |
|
|
FOLD
36
DELISTED
Amicus Therapeutics
FOLD
| $5.91M | 1.05% |
623,782
-619,100
| -50% | -$5.8M |
|
37
Arrowhead Research
ARWR
$11.9B
| $5.5M | 0.98% |
119,700
+14,900
| +14% | +$738K |
|
38
Certara
CERT
$1.26B
| $5.49M | 0.97% |
255,584
-94,854
| -27% | -$2.28M |
|
|
BLU
39
DELISTED
BELLUS Health Inc.
BLU
| $5.44M | 0.97% |
790,637
+68,671
| +10% | +$442K |
|
40
Intellia Therapeutics
NTLA
$1.49B
| $5.25M | 0.93% |
72,200
+600
| +0.8% | +$50.8K |
|
|
BPMC
41
DELISTED
Blueprint Medicines
BPMC
| $5.23M | 0.93% |
81,900
+16,100
| +24% | +$1.16M |
|
|
HZNP
42
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.21M | 0.92% |
49,475
+400
| +0.8% | +$39K |
|
43
Outset Medical
OM
$84.7M
| $5.05M | 0.9% |
+7,417
| New | +$4.46M |
|
44
Halozyme
HALO
$9.79B
| $5.03M | 0.89% |
+126,000
| New | +$4.49M |
|
45
Humana
HUM
$43.7B
| $5.01M | 0.89% |
11,525
+6,625
| +135% | +$2.77M |
|
46
STAAR Surgical
STAA
$1.21B
| $4.99M | 0.89% |
62,500
| – | – |
|
|
MRTX
47
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.92M | 0.87% |
59,837
-16,000
| -21% | -$1.64M |
|
48
Rocket Pharmaceuticals
RCKT
$340M
| $4.82M | 0.86% |
303,975
-79,000
| -21% | -$1.36M |
|
49
Merck
MRK
$322B
| $4.74M | 0.84% |
57,750
+7,500
| +15% | +$591K |
|
50
Boston Scientific
BSX
$69.5B
| $4.55M | 0.81% |
102,726
-27,500
| -21% | -$1.19M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q1 2022 Portfolio in Review
As of Q1 2022, Sectoral Asset Management held 123 positions worth $563M, down 15% from $664M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Sectoral Asset Management withdrew a net $27M in Q1 2022, closing 17 positions and reducing 43 holdings. Its most notable exit was Arena Pharmaceuticals Inc, an estimated $21.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Industrials.
Against the trend, Sectoral Asset Management opened a new position in Biohaven Pharmaceutical Holding Company Ltd. worth $12.6M.
- Sectoral Asset Management's largest Q1 2022 buy was Biohaven Pharmaceutical Holding Company Ltd.: 105,850 shares worth $12.6M.
- Sectoral Asset Management added most to BioMarin Pharmaceuticals in Q1 2022, an estimated $7.95M increase.
- Sectoral Asset Management's biggest Q1 2022 reduction was Amicus Therapeutics, cutting an estimated $5.8M.
- Sectoral Asset Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $21.4M.
- Sectoral Asset Management's ten largest holdings make up 25% of its $563M portfolio in Q1 2022.
- Sectoral Asset Management opened 15 new positions and closed 17 in Q1 2022.
- Sectoral Asset Management's portfolio value fell 15% quarter-over-quarter to $563M.
Based on Sectoral Asset Management's 13F filing for Q1 2022, filed 10 May 2022.